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Osteogenesis and bone remodeling are complex biological processes that are essential for the formation of new
bone tissue and its correct functioning. When the balance between bone resorption and formation is disrupted,
bone diseases and disorders such as Paget’s disease, fibrous dysplasia, osteoporosis and fragility fractures may
result. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss
that are based on the inhibition of bone resorption by osteoclasts or the stimulation of bone formation by
osteoblasts. Bisphosphonates, antiresorptive agents that reduce bone resorption, are usually recommended as
first-line therapy in women with postmenopausal osteoporosis. Numerous studies have shown that bispho-
sphonates are able to significantly reduce the risk of femoral and vertebral fractures. Other antiresorptive
agents indicated for the treatment of osteoporosis include selective estrogen receptor modulators, such as
raloxifene. Denosumab, a human monoclonal antibody, is another antiresorptive agent that has been approved
in Europe and the USA. This agent blocks the RANK/RANKL/OPG system, which is responsible for osteoclastic
activation, thus reducing bone resorption. Other approved agents include bone anabolic agents, such as
teriparatide, a recombinant parathyroid hormone that improves bone microarchitecture and strength, and
strontium ranelate, considered to be a dual-action drug that acts by both osteoclastic inhibition and
osteoblastic stimulation. Currently, anti-catabolic drugs that act through the Wnt-b catenin signaling pathway,
serving as Dickkopf-related protein 1 inhibitors and sclerostin antagonists, are also in development. This concise
review provides an overview of the drugs most commonly used for the control of osteogenesis in bone diseases.
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& INTRODUCTION
Osteoblasts play a crucial role both in the promotion of
bone formation and, indirectly, in the modulation of
osteoclast differentiation through the expression of the
receptor activator of nuclear factor NFkB ligand (RANKL)
and of osteoprotegerin (OPG), which are known, together
with RANK, to regulate osteoclast formation and activity
(1,2). RANKL, a transmembrane protein that is highly
expressed by pre-osteoblasts and osteoblasts (3), periosteal
cells (4), and osteocytes (5), binds and activates its receptor
RANK, which is mainly expressed by osteoclasts and their
precursors (6). After binding to RANK, RANKL stimulates
the formation, activity and survival of osteoclasts (7,8),
resulting in increased bone resorption (9). OPG, a member
of the tumor necrosis factor (TNF) superfamily of proteins
that is secreted by osteoblasts, is another key molecule in
this process because it inhibits RANKL-induced osteoclas-
togenesis (13). In fact, OPG binds to RANKL with high
affinity and competes with RANK for binding to RANKL on
the surface of osteoclasts and their precursors (10,11). This
RANK/RANKL/OPG system is regulated by various
cytokines (interleukin (IL)-1, 4, 6, 11 and 17 and TNF-a),
hormones (glucocorticoids, vitamin D and estrogen), and
mesenchymal transcription factors (cbfa-1 and peroxisome
proliferator-activated receptor gamma) (9) and determines
osteoclast activity (Figure 1).
Bone is continually reabsorbed and formed. This process
is called bone remodeling, in which bone cells have an
extremely important role in ensuring a balance between the
processes of bone formation and resorption. When this
balance is disrupted, various diseases and conditions, such
as osteogenesis imperfecta, tumors, osteoarthritis and
osteoporosis may arise. In particular, osteoporosis is
characterized by a progressive loss of bone mass and
microarchitecture, which leads to increased fracture risk.
Currently, the available drugs used in the treatment of
bone diseases can be divided into two categories: antiresorp-
tive agents, such as bisphosphonates (BPs), estrogen,
selective estrogen receptor modulators (SERMs) and
RANKL inhibitors that inhibit osteoclastogenesis and bone-
forming agents that increase bone strength by increasing
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bone mass, such as parathyroid hormone (PTH) peptides,
strontium ranelate (SR) and anti-Dickkopf-related protein 1
(DKK1) and anti-sclerostin (SOST) antibodies (Figure 2 and
Table 1).
The purpose of this review is to provide an overview of
the drugs commonly used for the control of osteogenesis in
bone diseases.
Bisphosphonates
BPs are a class of drugs generally used in the treatment
of bone disorders that are characterized by excessive
osteoclastic bone resorption, such as osteoporosis, Paget’s
disease, fibrous dysplasia, hypercalcemia of malignancy,
and inflammation-related bone loss (12-15).
The clinical efficacy of BPs primarily stems from two key
properties: their ability to bind strongly to bone mineral and
their inhibitory effects on mature osteoclasts (16).
In fact, these drugs are able to bind with high affinity to
hydroxyapatite crystals, where they remain for prolonged
periods. The drugs then act selectively on osteoblasts,
particularly in areas of high bone turnover, resulting in an
antiresorptive effect (17,18). The drugs are subsequently
released from the bone matrix upon exposure to acid and
enzymes secreted by active osteoclasts (19,20).
Studies to date suggest that the mechanisms by which BPs
are internalized by osteoclasts are similar for different BPs,
which can be divided into two categories: nitrogen-contain-
ing BPs and non- nitrogen-containing BPs.
Nitrogen-containing BPs, such as alendronate, ibandro-
nate, pamidronate, risedronate, and zoledronate, have a side
chain that contains a nitrogen atom, in contrast to the non-
nitrogen-containing BPs, such as clodronate and etidronate.
Nitrogen-containing BPs principally act by inhibiting
farnesyl pyrophosphate (FPP) synthase, an enzyme in the
cholesterol synthesis pathway and preventing the prenyla-
tion of small guanosine triphosphate (GTP)-binding pro-
teins, which are indispensable for cytoskeletal organization
and vesicular traffic in the osteoclast, causing osteoclast
inactivation (21,22).
In contrast, in osteoclasts’ cytosol, non-nitrogen-contain-
ing BPs are metabolized into adenosine triphosphate (ATP)
analogs that block osteoclast function and induce osteoclast
apoptosis (23).
Figure 1 - RANK/RANKL/OPG system. Osteoblasts produce RANKL and OPG under the control of various cytokines, hormones, and
growth factors. OPG binds and inactivates RANKL, resulting in the inhibition of osteoclastogenesis. In the absence of OPG, RANKL
activates its receptor, RANK, expressed on osteoclasts and preosteoclast precursors. The RANK-RANKL interaction leads to preosteoclast
recruitment and fusion into multinucleated osteoclasts and to osteoclast activation and survival.
Figure 2 - Summary of the main drugs used in the control of
osteogenesis.
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In vitro, several BPs inhibit osteoclast differentiation in
human bone marrow cultures (24) and promote the
apoptosis of murine osteoclasts, which was also confirmed
by in vivo studies in mice. More specifically, in vitro studies
have shown that BPs are not always selective for osteoclasts
and can inhibit cell growth and induce apoptosis in a wide
range of cell types (16,19,25-28) and in many cancer cell
types (20) at high doses.
In the 1990s, in vitro studies demonstrated that osteoblasts
treated with BPs did not exhibit osteoclastogenesis (29,30).
Additionally, numerous studies performed to evaluate the
effects of BPs on osteoblasts have demonstrated the non-
selectivity of these drugs for osteoclastic cells.
In addition, BPs are able to inhibit the apoptosis of
osteocyte cell lines and primary murine osteoblasts (31), as
well as human osteoblasts (32).
Nitrogen-containing BPs appear to induce collagen type
I (COLIA1) gene expression (28). Moreover, alendronate
and etidronate enhance IL-6 production in osteoblasts
(33).
Clodronate stimulates osteoblast differentiation in ST2
and MC3T3-E1 cells, whereas etidronate promotes osteoin-
duction only in MC3T3-E1 cells (34). In addition, it has been
shown that BPs decrease the expression of RANKL and
increase the expression of OPG in human osteoblastic cells
(35,36). Finally, trabecular cultures of MG-63 cells and
primary human bone have shown that risedronate and
alendronate each increase osteoblast and osteoblast pro-
genitor numbers and also enhance the gene expression of
bone morphogenetic protein 2 (BMP-2), COLIA1, and
osteocalcin (OCN) (37,38).
It has been demonstrated that these drugs increase the
proliferation and formation of mineralized nodules in
murine and human bone marrow cultures in vitro (25,39-
42) and promote early osteoblastogenesis in both young and
aged mice in vivo (39). In contrast, other studies have
demonstrated that BPs decrease proliferation and inhibit
osteoblast differentiation and mineralization (27,28,43,44).
In particular, an in vitro study has demonstrated that
pamidronate and zoledronate decrease osteoblast prolifera-
tion in a dose-dependent manner and increase differentia-
tion and bone-forming activities among immortalized
human fetal osteoblasts (28). However, another in vitro
study on mouse calvarial osteoblasts has shown that
pamidronate and alendronate inhibit osteoblast growth
and bone nodule formation (43).
These conflicting results are explained by the fact that low
concentrations of BPs, from 1029 M to 1026 M, were shown to
increase growth and have induction effects, whereas con-
centrations higher than 1025 M had inhibitory effects (45).
Finally, BPs such as alendronate, risedronate, and zoledro-
nate have been shown to reduce the risk of new vertebral,
non-vertebral, and hip fractures (46-49). Interestingly, the
long-term use (up to 10 years) of BPs in the treatment of
osteoporosis has been associated with a good safety profile
(50), although several studies have associated BP therapy
with a potential risk of osteonecrosis of the jaw and atypical
subtrochanteric femoral fractures (51-53).
Denosumab
The RANK/RANKL/OPG pathway is key to maintaining
the balance between the activities of osteoblasts and
Table 1 - Comparisons of the principal drugs used in bone diseases.
Drugs
Bone
resorption
inhibitors
Bone-forming
agents In vitro effects In vivo effects
Bisphosphonates - Inhibition of osteoclast activity and
differentiation
- Induction of osteoclast apoptosis
- Reduction in the risk of
new vertebral,
non-vertebral, and hip
fractures
Denosumab - Inhibition of osteoclast differentiation,
activation and survival
- Increase in bone mass and decrease
in the risk of fractures
Selective Estrogen Receptor
Modulators (SERMs)
- Reduction in the number of
preosteoclasts and mature
osteoclasts
- Reduction in the risk of
new vertebral fractures
Intermittent PTH1-34 Therapy - Increase in the number and
activity of osteoblasts
- Increase in osteogenesis
and chondrogenesis during
skeletal repair
- Increase in bone mineral
density
- Enhancement of the cortical
thickness and trabecular
bone volume and
improved bone
microarchitecture
Strontium Ranelate - Induction of the osteoblastic
differentiation of human MSCs
- Increase in osteoblast
proliferation, survival and
differentiation
- Reduction in osteoblast
apoptosis
- Decrease in osteoclast
differentiation
- Increase in osteoclast
apoptosis
- Increase in bone mineral
density
- Reduction in the risk of
new vertebral, non-
vertebral, and hip
fractures
Anti-DKK1 and Anti-SOST
Antibodies
- Increase in osteoblastogenesis
and proliferation
- Increased bone formation,
trabecular thickness, and bone
mass and strength
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osteoclasts to prevent bone loss and ensure normal bone
turnover. Thus, manipulation of the RANKL system has
been a target of pharmaceutical development. In particular,
human OPG constructs, such as OPG fusion proteins (OPG-
Fc) (54), have been valuable research tools because they
strongly inhibit bone resorption in a variety of species,
including rats (55,56), pigs (57), monkeys (58), and humans
(54,59). However, the clinical development of OPG-Fc was
abandoned in favor of denosumab due to several limitations
concerning half-life and specificity. Denosumab (AMG 162)
is currently the only RANKL-targeted therapy available,
offering a new approach in the treatment of osteoporosis
(60,61). This human monoclonal IgG2 antibody was devel-
oped using transgenic mouse technology. Denosumab binds
RANKL with high affinity and specificity, thereby inhibiting
osteoclastogenesis, as demonstrated by numerous studies
(61-65) and also increasing bone mass and reducing the risk
of fractures (66).
Finally, several studies have demonstrated that denosu-
mab is able to reduce the expression of specific markers of
bone resorption in postmenopausal women (67) and in
subjects with bone metastases or multiple myeloma (68).
Selective Estrogen Receptor Modulators
SERMs, such as estrogen, are potent inhibitors of bone
resorption and are currently Food and Drug Administration
(FDA) approved for the prevention and treatment of
osteoporosis in postmenopausal women (69). In particular,
estrogen is a systemic hormone with direct effects on bone
that plays an important role in osteoporosis. In postmeno-
pausal women, the deficiency of estrogen leads to an
upregulation of RANKL on bone marrow cells, resulting
in an increase in bone resorption (70).
In contrast, estrogen itself stimulates OPG production in
osteoblasts and thus exerts antiresorptive effects on bone
(71). The extraskeletal effects of estrogen deficiency are
mainly based on increased renal calcium excretion and
decreased intestinal calcium absorption (72,73). Tamoxifen
was the first SERM to be widely used in clinical practice,
based on its now well-recognized estrogen antagonist
activity in the breast.
The prolonged use of tamoxifen was associated with an
increase in uterine cancer (74), leading to the search for
other SERMs with different pharmacological profiles. Thus,
raloxifene, a new SERM, was developed for the treatment
and prevention of postmenopausal osteoporosis, with the
goal of improving the drug safety profile. Raloxifene has a
spectrum of tissue-specific agonist-antagonist effects on
estrogen target tissues but acts on bone as an estrogen
agonist (75). This drug has been extensively studied and
data support its estrogen agonist profile in the skeletal
system. The drug specifically acts on estrogenic receptor-a
and estrogenic receptor-b, binding to the receptors in the
same ligand-binding pocket as does estradiol, and causes
the C-terminal a-helix of the receptor to change its
conformation to block access to the activation function-2
region of the receptor. This event in turn likely blocks access
to the transcriptional coactivators necessary to facilitate the
activation of estrogen-responsive genes (76). In the ovar-
iectomized (OVX) rat model, raloxifene acts as an anti-
resorptive, with preservation of both bone mineral density
(BMD) and bone strength (76). It has been demonstrated
that raloxifene modulates the homeostasis of bone cells in
vitro by inhibiting osteoclastogenesis and bone resorption,
reducing the number of preosteoclasts and mature osteo-
clasts in OVX rats (77) by suppressing osteoblast apoptosis
and increasing osteoblast proliferation and differentiation in
MC3T3-E1 cultures (78-80). Other studies in OVX rats have
shown that raloxifene was able to decrease RANKL and
increase OPG expression (77,81,82). Finally, an in vitro study
on human fetal osteoblast cell lines treated with raloxifene,
which expressed a G-protein-coupled receptor (GPR30) but
lacked estrogen receptor, has shown that this drug was able
to induce cell proliferation, although the function of GPR30
in bone remains unclear (83).
Parathyroid Hormone Therapy
The first molecule to be approved by the FDA as the only
anabolic therapy for osteoporosis was a PTH analog (84).
This analog is available in the form of human recombinant
PTH peptide 1-34 (teriparatide, or PTH1-34), a fragment of
PTH that has similar affinity for PTH receptor-1.
PTH is released from the parathyroid gland, and its
secretion is chiefly controlled by serum [Ca2+] through
negative feedback (85).
Pharmacologically, when PTH is administered intermit-
tently (once daily) at low doses, it has an anabolic effect on
osteoblasts (85), stimulating bone formation both in vitro
and in vivo and increasing in BMD (84).
Many studies have demonstrated the efficacy of PTH1-34
therapy in a variety of skeletal repair models, suggesting
that PTH1-34 enhanced and accelerated not only bone
remodeling but also osteogenesis and chondrogenesis
during skeletal repair (87). In 1999, Andreassen et al. were
the first to report the efficacy of intermittent PTH1-34 therapy
on rat tibial fracture healing (88). In particular, it has been
shown that intermittent PTH administration promotes bone
formation by increasing the number and activity of
osteoblasts, enhances the mean cortical thickness and
trabecular bone volume and improves bone microarchitec-
ture (89). At the molecular level, PTH enhances Wnt
signaling through inhibition of the Wnt antagonist SOST
and induces the local production of bone anabolic growth
factors such as insulin-like growth factor 1 (IGF1) (86).
Furthermore, PTH1-34 enhances the differentiation of
mesenchymal stem cells (MSCs) into osteoblasts via the
induction of osterix (OSX) and Runt-related transcription
factor 2 (RUNX-2) expression in vitro, increasing both OSX
expression at the fracture site in vivo and the expression of
osteoblastic marker genes, including COLIA1 and OCN
(90). Several studies have shown that PTH1-34 can promote
the proliferation and differentiation of MSCs in the early
phase of bone healing (91) and to induce the proliferation of
chondroprogenitors at a fracture site, contributing to
increased bone formation during fracture healing (92) and
accelerating articular cartilage repair (87,93,94), respectively.
These data were supported by clinical studies that have
demonstrated positive effects of intermittent PTH therapy,
including increasing bone mass and reducing the bone
fragility associated with osteoporosis due to age, sex
hormone deficiency and glucocorticoid therapy (95).
Conversely, in certain studies, toxicity has been reported
for the use of PTH therapy. In particular, the toxic effect of
treatment with teriparatide or parathyroid hormone 1-84,
which appears to be unique to animals and not applicable to
human subjects, is osteosarcoma (96). In fact, it has
been reported that rats treated with high doses of either
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teriparatide or parathyroid hormone 1-84 for prolonged
periods of time developed osteosarcoma (97-99).
Treatment with teriparatide is approved by the FDA for a
limited duration, from 18-24 months and in many European
countries, approval is limited to 18 months. However, in
several studies, the period of treatment with teriparatide
was prolonged to 24-30 months (100,101).
Although it has been reported that the teriparatide-
related risk of osteosarcoma development is low (102), there
are still no clear scientific data. The general recommenda-
tion for this treatment is to closely follow patients who have
risk factors, i.e., subjects with Paget’s disease, prior skeletal
irradiation, or unexplained increases in serum bone-specific
alkaline phosphatase (ALP) and adolescents in whom the
epiphyses have not yet closed (96).
Strontium Ranelate
SR is a drug commonly used for the treatment of
osteoporosis and fragility fractures (103,104). SR consists
of two cations of strontium, representing the active
component, and one anion of ranelate, which acts as a
carrier (105). In contrast to other drugs, SR has a dual effect
on bone remodeling, both stimulating bone formation and
decreasing bone resorption. In vitro experiments have
shown that SR increased osteoblastic activity, enhancing
preosteoblastic cell proliferation and differentiation
(7,11,106,107) and stimulating osteoblastic differentiation
markers, such as ALP, hydroxyapatite (HA) deposit forma-
tion, bone sialoprotein (BSP), and OCN, in primary murine
osteoblasts (108).
In addition, in in vitro animal models, SR was observed to
reduce osteoblast apoptosis (9,107) and to decrease osteo-
clast differentiation marker expression, with an enhance-
ment of osteoclast apoptosis (109-111). Furthermore, in vitro
data on primary human osteoblasts indicate that this drug
promotes the ultimate differentiation of osteoblasts into
osteocytes, as indicated by the increased expression of
SOST, a marker of osteoblast differentiation (106). In vitro
studies on rodent (112,113) and human (106) primary
osteoblast cultures have shown that SR, similar to calcium,
acts as an agonist of the calcium-sensing receptor (CaSR),
promotes cell proliferation (106,112) via activation of the
CaSR, and increases bone cell differentiation (106,113) and
bone cell survival (106).
SR induces osteoblastic differentiation of human MSCs,
stimulating the expression of genes of the bone extracellular
matrix: COLIA1, BSP, OCN and RUNX-2. These genes are
essential for osteoinduction (114). Furthermore, numerous
studies using various cellular models have been performed
to evaluate the effects of strontium in combination with
different biomaterials on osteogenesis (115-119). In particu-
lar, it has been demonstrated that strontium released into
the culture medium by a previously loaded amidated
carboxymethylcellulose (CMCA) hydrogel was able to
promote osteoinduction as detected based on the produc-
tion of ALP and the formation of HA deposits in a clonal cell
line derived from human adipose tissue-derived MSCs
(120).
Wnt/b-catenin Pathway Antagonists
The Wnt/b-catenin pathway plays an important role in
the main processes controlling osteogenesis (121). This
pathway regulates the gene transcription of proteins
important for osteoblast function (63).
In vitro and in vivo experiments have shown that
activation of the canonical Wnt/b-catenin pathway induces
the cellular replication and differentiation of osteoblasts,
reducing adipogenic differentiation in MSCs (122,123).
The Wnt pathway is composed of Wnt proteins, frizzled
transmembrane receptors and low-density lipoprotein
receptor-related protein 5/6 (LRP5/6). Wnt signaling is
activated by the presence of the Wnt ligand, which interacts
with its receptor, thereby inhibiting the receptor. This
interaction leads to cytoplasmic accumulation of b-catenin,
which translocates to the nucleus, activating a fundamental
transcription factor, RUNX-2, involved in osteogenic differ-
entiation. However, in the absence of the Wnt ligand, b-
catenin is phosphorylated by glycogen synthase kinase 3
beta (GSK3B), leading to its degradation, and gene
transcription is halted (124). Various studies have demon-
strated that modifications in Wnt signaling contributed to
age-related bone loss in mouse models (125). In aged or
OVX osteopenic mice, with the use of GSK3B, the Wnt
signaling cascade enhanced bone formation and increased
trabecular and cortical bone density and bone strength
(126,127).
Studies of the Wnt/b-catenin pathway have led to the
further discovery of inhibitors of Wnt signaling that are
secreted by osteocytes. These inhibitors include SOST and
DKK1 protein, which are Wnt antagonists specific to bone.
Both block the binding of Wnt to LRP5, thereby inhibiting
osteoblast stimulation (64,128). In fact, it has been observed
that a loss-of-function mutation of SOST leads to an increase
in bone formation and bone mass (129). Many forms of
cancer are associated with such mutations within the Wnt
signaling pathway (130,131).
Currently, based on promising results in animal models,
monoclonal antibodies designed to block the inhibitory
action of both SOST and DKK1 have been introduced for use
in clinical trials (65,66,132-134).
The development of pharmacological SOST and DKK1
antagonists that increase bone formation and bone mass is a
new strategy in the treatment of bone disorders. In vivo
studies on monkeys and OVX rats have shown that systemic
administration of an anti-SOST MAB increased bone
formation, bone mass, and strength (135). Furthermore,
the anti-SOST antibody was able to enhance bone formation
markers in postmenopausal women (136). Finally, an
increase in bone formation on trabecular, periosteal,
endocortical, and intracortical surfaces, without increased
bone resorption and with enhanced trabecular thickness,
BMD and bone strength, was shown in preclinical studies
with the administration of SOST-neutralizing monoclonal
antibodies (137,138).
Today, the prevention and treatment of several bone
disorders are possible. This progress is due to the develop-
ment of a variety of drugs that act to halt excessive bone
resorption by inhibiting osteoclasts or by promoting bone
formation.
BPs such as alendronate and zoledronic acid have been
demonstrated to significantly reduce the risk of vertebral,
non-vertebral and femoral fractures by decreasing bone
remodeling via the inhibition of osteoclasts with increased
bone mass, although their long-term use has been correlated
with the occurrence of atypical femoral fractures (53).
However, a new approach targeting the inhibition of
osteoclast activity inhibits RANKL, which is involved in
the survival and differentiation of mature osteoclasts.
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Denosumab is among the RANKL inhibitors that have been
most studied and used, and numerous studies have
demonstrated that denosumab exerts an inhibitory action
on osteoclastogenesis (61-65).
In animal models, it has been demonstrated that
teriparatide accelerates bone fracture healing, thereby
enhancing bone remodeling (139). In studies of bone
histomorphometry, PTH1-34 was able to increase the
trabecular bone mass in postmenopausal women (140).
Raloxifene also modulates the homeostasis of bone cells in
vitro by inhibiting osteoclastogenesis and bone resorption,
with a reduction in the numbers of preosteoclasts and
mature osteoclasts in OVX rats (77). Additionally, it has
been shown that raloxifene suppressed osteoblast apoptosis
in MC3T3-E1 cells (78) and increased osteoblast prolifera-
tion and differentiation in murine cell cultures (79,80).
Finally, in vitro studies have demonstrated that SR promotes
the survival, proliferation and differentiation of osteoblasts
and inhibits osteoclastic activity and clinical studies have
shown that SR improves bone strength, increasing BMD.
Furthermore, no change in the porosity of bone was evident
in patients treated with SR (141).
In conclusion, an understanding of the molecular and
cellular mechanisms of bone fragility is essential for the
development of successful cell therapies that support new
pharmacological approaches.
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